𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome

✍ Scribed by David Raveh; Ovadia Shemesh; Yaakov Jack Ashkenazi; Robert Winkler; Vivian Barak

Book ID
106159606
Publisher
Springer
Year
2004
Tongue
English
Weight
191 KB
Volume
19
Category
Article
ISSN
0931-041X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Listeria monocytogenes infection as a co
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α–neutralizing agents
✍ Nancy R. Slifman; Sharon K. Gershon; Jong-Hoon Lee; Evelyne T. Edwards; M. Miles 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract ## Objective Tumor necrosis factor α (TNFα) has been implicated in the pathogenesis of certain inflammatory diseases. Two TNFα‐neutralizing agents are licensed in the US. Infliximab is licensed for the treatment of Crohn's disease (CD) and, when used with methotrexate, for the treatmen

Outcomes after switching from one anti–t
Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
✍ Kimme L. Hyrich; Mark Lunt; Kath D. Watson; Deborah P. M. Symmons; Alan J. Silma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti‐TNF agent, although the benefits of switching are unknown. The pres